Related people
Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.
Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.
Since 2020 | Partner, Taylor Wessing |
2016 - 2020 | Senior Counsel, Taylor Wessing |
2010 - 2016 | Senior Associate, Taylor Wessing |
2006 - 2010 | Associate,Taylor Wessing |
2004 - 2006 | Associate, Linklaters |
2002 - 2004 | Trainee, Linklaters |
2013 | MSc Energy Environmental Technology and Economics, London City University |
2005 | Diploma in Intellectual Property Law and Practice, Bristol University |
2004 | Admitted as a lawyer, England, Wales |
2000 | Graduate Diploma in Law, Nottingham Law School |
1998 | BSc in Cell Biology, Durham University |
English |
Latest news & insights
Word on the street at the J.P. Morgan Healthcare Conference 2024
by multiple authors
Advising Essential Pharma on its acquisition of European rights to Colobreathe®
by multiple authors
Advising gene therapy company AlveoGene on its complex spinout and launch investment
by multiple authors
Theramex enters into an exclusive licensing agreement with Radius Health Inc to commercialise ELADYNOS®
by Colin McCall and Charlie Adams